Enzyme-catalyzed production of the neuroprotective NMDA receptor antagonist 7-chlorokynurenic acid in the rat brain in vivo

European Journal of Pharmacology

Volumn 319, Issue 1, 1997, Pages 13-20

  Wu, Hui Qiu ^a   Salituro, Francesco G ^b,c   Schwarcz, Robert ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^b Merrell Dow Research Institute   (United States)

^c VERTEX PHARMACEUTICALS   (United States)

Author keywords

Astrocyte; Excitotoxicity; Glycine site; Kynurenic acid; Neurodegenerative disorder; NMDA receptor; Quinolinic acid

Indexed keywords

7 CHLOROKYNURENIC ACID; GLIOTOXIN; GLUTAMATE DECARBOXYLASE; KYNURENIC ACID DERIVATIVE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; QUINOLINIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; ENZYME ACTIVITY; HIPPOCAMPUS; HISTOLOGY; INTRACEREBRAL DRUG ADMINISTRATION; MALE; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BRAIN; CITRATES; EXCITATORY AMINO ACID ANTAGONISTS; KYNURENIC ACID; MALE; NEUROPROTECTIVE AGENTS; QUINOLINIC ACID; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0031566868     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(96)00829-1     Document Type: Article

References (49)

1. Balster, R.L., R.S. Mansbach, K.L. Shelton, K.L. Nicholson, D.M. Grech, J.L. Wiley, H. Li and E. Weber, 1995, Behavioral pharmacology of two novel substituted quinoxalinedione glutamate antagonists, Behav. Pharmacol. 6, 577.
2. Baron, B.M., B.L. Harrison, F.P. Miller, I.A. McDonald, F.G. Salituro, C.J. Schmidt, S.M. Sorensen, H.S. White and M.G. Palfreyman, 1990, Activity of 5,7-dichlorokynurenic acid, a potent antagonist at the N-methyl-D-aspartate receptor-associated glycine binding site, Mol. Pharmacol. 38, 554.
3. Blight, A.R., T.I. Cohen, K. Saito and M.P. Heyes, 1995, Quinolinic acid accumulation and functional deficits following experimental spinal cord injury, Brain 118, 735.
4. Bradford, M.M., 1976, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Anal. Biochem. 72, 248.
5. Buchli, R., D. Alberati-Giani, P. Malherbe, C. Köhler, C. Broger and A.M. Cesura, 1995, Cloning and functional expression of a soluble form of kynurenine/α-aminoadipate aminotransferase from rat kidney, J. Biol. Chem. 270, 29330.
6. Chapman, A.G., N. Dürmüller, B.L. Harrison, B.M. Baron, N. Parvez and B.S. Meldrum, 1995, Anticonvulsant activity of a novel NMDA/glycine site antagonist, MDL 104,653, against kindled and sound-induced seizures, Eur. J. Pharmacol. 274, 83.
7. Coderre, T.J. and I. Van Empel, 1994, The utility of excitatory amino acid (EAA) antagonists as analgesic agents. II. Assessment of the antinociceptive activity of combinations of competitive and noncompetitive NMDA antagonists with agents acting at allosteric-glycine and polyamine receptor sites, Pain 59, 353.
8. Croucher, M.J. and H.F. Bradford, 1990, 7-Chlorokynurenic acid, a strychnine-insensitive glycine receptor antagonist, inhibits limbic seizure kindling, Neurosci. Lett. 118, 29.
9. Faiman, C.P., E. Viu, P. Skolnick and R. Trullas, 1994, Differential effects of compounds that act at strychnine-insensitive glycine receptors in a punishment procedure, J. Pharmacol. Exp. Ther. 270, 528.
10. Foster, A.C., C.L. Willis and R. Tridgett, 1990, Protection against N-methyl-D-aspartate receptor-mediated neuronal degeneration in rat brain by 7-chlorokynurenate and 3-amino-1-hydroxypyrrolid-2-one, antagonists at the allosteric site for glycine, Eur. J. Neurosci. 2, 270.
11. Fukui S., R. Schwarcz, S.I. Rapoport, Y. Takada and Q.R. Smith, 1991, Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism, J. Neurochem. 56, 2007.
12. Grotta, J., W. Clark, B. Coull, L.C. Pettigrew, B. Mackay, L.B. Goldstein, I. Meissner, D. Murphy and L. LaRue, 1995, Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke - Results of a phase IIa randomized trial, Stroke 26, 602.
13. Hargreaves, R.J., M. Rigby, D. Smith and R.G. Hill, 1993, Lack of effect of L-687,414 ((+)-cis-4-methyl-HA-966), an NMDA receptor antag-onist acting at the glycine site, on cerebral glucose metabolism and cortical neuronal morphology, Br. J. Pharmacol. 110, 36.
14. Herman, B.H., F. Vocci and P. Bridge, 1995, The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal, Neuropsychopharmacology 13, 269.
15. Hokari, M., H.-Q. Wu, R. Schwarcz and Q.R. Smith, 1996, Facilitated brain uptake of 4-chlorokynurenine and conversion to 7-chlorokynurenic acid, NeuroReport, in press.
16. Johnson, J.W. and P. Ascher, 1987, Glycine potentiates the NMDA response in cultured mouse brain neurons, Nature 325, 529.
17. Kemp, J.A., A.C. Foster, P.D. Leeson, T. Priestley, R. Tridgett, L.L. Iversen and G.N. Woodruff, 1988, 7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex, Proc. Natl. Acad. Sci. USA 85, 6547.
18. Kessler, M., T. Terramani, G. Lynch and M. Baudry, 1989, A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists, J. Neurochem. 52, 1319.
19. Koek, W. and F.C. Colpaert, 1990, Selective blockade of N-methyl-D-aspartate (NMDA)-induced convulsions by NMDA antagonists and putative glycine antagonists: relationship with phencyclidine-like behavioral effects, J. Pharmacol. Exp. Ther. 252, 349.
20. Kristensen, J.D., R. Karlsten, T. Gordh and O.-G. Berge, 1994, The NMDA antagonist 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP) has antinociceptive effect after intrathecal injection in the rat, Pain 56, 59.
21. Kulagowski, J.J., R. Baker, N.R. Curtis, P.D. Leeson, I.M. Mawer, A.M. Moseley, M.P. Ridgill, M. Rowley, I. Stansfield, A.C. Foster, S. Grimwood, R.G. Hill, J.A. Kemp, G.R. Marshal, K.L. Saywell and M.D. Tricklebank, 1994, 3′-(Arylmethyl)-and 3′-(aryloxy)-3-phenyl-4-hydroxyquinolin-2 (1H)-ones: orally active antagonists of the glycine site on the NMDA receptor, J. Med. Chem. 37, 1402.
22. Leeson, P.D. and L.L. Iversen, 1994, The glycine site on the NMDA receptor-activity relationships and therapeutic potential, J. Med. Chem. 37, 4053.
23. Lipton, S.A. and P.A. Rosenberg, 1994, Mechanisms of disease -excitatory amino acids as a final common pathway for neurologic disorders, N. Engl. J. Med. 330, 613.
24. McQuaid, L.A., E.C.R. Smith, D. Lodge, E. Pralong, J.H. Wikel, D.O. Calligaro and P.J. O'Malley, 1992, 3-Phenyl-4-hydroxyquinolin-2 (1H)-ones: potent and selective antagonists at the strychnine-insensitive glycine site on the N-methyl-D-aspartate receptor complex, J. Med. Chem. 35, 3423.
25. Muir K.W. and K.R. Lees, 1995, Clinical experience with excitatory amino acid antagonist drugs, Stroke 26, 503.
26. Namba, T., K. Morimoto, N. Yamada and S. Otsuki, 1993, Antiepileptogenic action of 7-chlorokynurenic acid on amygdala kindling of rats, Pharmacol. Biochem. Behav. 46, 275.
27. Näsström, J., U. Karlsson and C. Post, 1992. Antinociceptive actions of different classes of excitatory amino acid receptor antagonists in mice, Eur. J. Pharmacol. 212, 21.
28. Okuno, E., W. Schmidt, D.A. Parks, M. Nakamura and R. Schwarcz, 1991, Measurement of rat brain kynurenine aminotransferase at physiological kynurenine concentrations, J. Neurochem. 57, 533.
29. Olney, J.W. and N.B. Farber, 1995, Glutamate receptor dysfunction and schizophrenia, Arch. Gen. Psychiatry 52, 998.
30. Paul, I.A., G. Nowak, R.T. Layer, P. Popik and P. Skolnick, 1994, Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments, J. Pharmacol. Exp. Ther. 269, 95.
31. Paulsen, R.E., A. Contestabile, L. Villani and F. Fonnum, 1987, An in vivo model for studying function of brain tissue temporarily devoid of glial cell metabolism: the use of fluorocitrate, J. Neurochem. 48, 1377.
32. Perkins, M.N. and T.W. Stone, 1982, An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid, Brain Res. 247, 184.
33. Roberts, R.C., F. Du, K. McCarthy, E. Okuno and R. Schwarcz, 1992, Immunocytochemical localization of kynurenine aminotransferase in the rat striatum. A light and electron microscopic study, J. Comp. Neurol. 326, 82.
34. Rogawski, M.A., 1992, The NMDA receptor, NMDA antagonists and epilepsy therapy - a status report, Drugs 44, 279.
35. Salituro, F.G., R.C. Tomlinson, B. Baron, M.G. Palfreyman, I.A. McDonald, W. Schmidt, H.-Q. Wu, P. Guidetti and R. Schwarcz, 1994, Enzyme activated antagonists of the strychnine-insensitive glycine/NMDA receptor, J. Med. Chem. 37, 334.
36. 3H]kynurenine as a substrate, Neuroscience 55, 177.
37. Schwarcz, R., 1992, Excitotoxins, kynurenines and neuropsychiatric diseases: implications for drug development, in: Drug Research Related to Neuroactive Amino Acids, eds. A. Schoesboe, N.H. Diemer and H. Kofod (Munksgaard, Copenhagen), p. 287.
38. Schwarcz, R., C. Köhler, K. Fuxe, T. Hökfelt and M. Goldstein, 1979, On the mechanism of selective neuronal degeneration in the rat brain: studies with ibotenic acid, Adv. Neurol. 23, 655.
39. Schwarcz, R., J.F. Collins and D.A. Parks, 1982, α-Amino-ω-phosphonocarboxylates block ibotenate but not kainate neurotoxicity in rat hippocampus, Neurosci. Lett. 33, 85.
40. Schwarcz, R., W.O. Whetsell, Jr. and R.M. Mangano, 1983, Quinolinic acid: an endogenous metabolite that causes axon-sparing lesions in rat brain, Science 219, 316.
41. Schwarcz, R., P. Guidetti and R.C. Roberts, 1996, Quinolinic acid and kynurenic acid: glia-derived modulators of excitotoxic brain injury, in: The Role of Glia in Neurotoxicity, eds. M. Aschner and H.K. Kimelberg (CRC Press, Boca Raton, FL), p. 245.
42. +-independent transporter of neutral amino acids in astrocytes, J. Neurosci. 9, 2066.
43. Trujillo, K.A. and H. Akil, 1991, Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801, Science 251, 85.
44. Trullas, R., B. Jackson and P. Skolnick, 1989, Anxiolytic properties of 1-aminocyclopropanecarboxylic acid, a ligand at strychnine-insensitive glycine receptors, Pharmacol. Biochem. Behav. 34, 313.
45. Walsh, J.L., W.P. Todd, B.K. Carpenter and R. Schwarcz, 1991, 4-Halo-3-hydroxy-anthranilic acids: potent competitive inhibitors of 3-hydroxyanthranilic acid oxygenase in vitro. Biochem. Pharmacol. 42, 985.
46. Watkins, J.C. and Collingridge, G.L. (eds.) (1994) The NMDA Receptor, 2nd edn. (IRL Press, Oxford).
47. Witkin, J.M., S. Brave, D. French and B. Geter-Douglass, 1995, Discriminative stimulus effects of [(+)-HA-966], a partial agonist of the strychnine-insensitive modulatory site of the N-methyl-D-aspartate receptor, J. Pharmacol. Exp. Ther. 275, 1267.
48. Wu, H.-Q. and R. Schwarcz, 1995, Cerebral production of 7-chlorokynurenic acid after systemic administration of its bioprecursor 4-chlorokynurenine in mice, Soc. Neurosci. Abstr. 21, 436.6.
49. Wu, H.-Q., H. Baran, U. Ungerstedt and R. Schwarcz, 1992, Kynurenic acid in the quinolinate-lesioned rat hippocampus: studies in vitro and in vivo, Eur. J. Neurosci. 4, 1264.